Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
93
datasets available to search
ShareScore release 0.9.0
Dataset results
93 results for “episodic migraine”
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
ClinicalTrials.gov study NCT00797667. IPD Sharing: YES. Countries: 0. Publications: 1.
Hypothalamus Connectivity in Chronic and Episodic Migraine
ClinicalTrials.gov study NCT02328976. IPD Sharing: NO. Countries: 1. Publications: 2.
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
ClinicalTrials.gov study NCT06004388. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
ClinicalTrials.gov study NCT05711394. IPD Sharing: YES. Countries: 16. Publications: 0.
Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration
ClinicalTrials.gov study NCT05690737. IPD Sharing: NO. Countries: 1. Publications: 1.
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects
ClinicalTrials.gov study NCT04473976. IPD Sharing: NO. Countries: 1. Publications: 26.
Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis
ClinicalTrials.gov study NCT04463875. IPD Sharing: NO. Countries: 1. Publications: 1.
DFN-11 Injection in Episodic Migraine With or Without Aura
ClinicalTrials.gov study NCT02569853. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine
ClinicalTrials.gov study NCT05416476. IPD Sharing: NO. Countries: 1. Publications: 7.
Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)
ClinicalTrials.gov study NCT04360148. IPD Sharing: Not stated. Countries: 1. Publications: 25.
Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM)
ClinicalTrials.gov study NCT03556722. IPD Sharing: NO. Countries: 1. Publications: 1.
TIzanidine for the Preventive Treatment of Episodic MigrainE (TIME)
ClinicalTrials.gov study NCT05484349. IPD Sharing: NO. Countries: 1. Publications: 7.
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065)
ClinicalTrials.gov study NCT01125774. IPD Sharing: YES. Countries: 0. Publications: 1.
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients
ClinicalTrials.gov study NCT04260035. IPD Sharing: NO. Countries: 1. Publications: 2.
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
ClinicalTrials.gov study NCT01513291. IPD Sharing: YES. Countries: 0. Publications: 1.
One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study - supplementary data
<p><b>Objective:</b> To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. </p> <p><b>Methods: </b>Patients were randomized (<i>n</i>=955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo, erenumab 70 or 140mg. At Week 24, 845 patients were re-randomized (1:1) to erenumab 70 or 140mg during the 28-week dose-blinded active-treatment phase (ATP). Monthly migraine days (MMD), achieving ≥50%, ≥75% and 100% reduction in MMD, and safety/tolerability were assessed. </p> <p><b>Results: </b>Mean MMD at DBTP baseline was 8.3. At Week 52, mean changes (SE) from pre-DBTP baseline/Week 24 (pre-ATP baseline) in MMD were −4.2 (0.2)/−1.1 (0.2) (70mg) and −4.6 (0.2)/−1.8 (0.2) (140mg) irrespective of treatment during the DBTP. For patients reducing dose from 140 (DBTP) to 70mg (ATP), change in MMD from Week 24 to 52 was −0.1 (0.3), and for those increasing from 70 (DBTP) to 140mg (ATP) was −1.8 (0.3). At Week 52, 61.0%, 38.5% and 19.8% of patients on erenumab 70mg, and 64.9%, 40.8% and 21.2% on erenumab 140mg, achieved ≥50%, ≥75% and 100% reduction in MMD from DBTP baseline, respectively. Among erenumab-treated patients in DBTP who showed ≥50% reduction in MMD during the last 3 months of DBTP and completed ATP, 86% showed sustained responses at ≥50% during the last 3 months of ATP. Safety of erenumab in the ATP was similar to the DBTP; exposure-adjusted incidence rates of adverse events were similar for either dose.</p> <p><b>Conclusion: </b>Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding. </p>
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
ClinicalTrials.gov study NCT06625060. IPD Sharing: YES. Countries: 14. Publications: 0.
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
ClinicalTrials.gov study NCT05217927. IPD Sharing: YES. Countries: 10. Publications: 0.
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
ClinicalTrials.gov study NCT02115269. IPD Sharing: Not stated. Countries: 2. Publications: 0.
A Functional MRI Study on Erenumab Treatment Effects in Episodic Migraine Patients
ClinicalTrials.gov study NCT03977649. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.